Vitrolife

Vitrolife FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vitrolife (VITR.ST) as of Nov 9, 2026 is -9.18 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 158.87 % — a change of -105.78% (lower).

FCF Conversion

-9.18 %

YoY

-105.78%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vitrolife is 2025 -9.18 % . FCF Conversion Rate (FCF/EBITDA) of Vitrolife was 2024 158.87 % . It decreases by -105.78% lower compared to the previous year.

The Vitrolife FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
54.68 SEK
Jan 1, 2019
85.23 SEK
Jan 1, 2020
117.26 SEK
Jan 1, 2021
94.39 SEK
Jan 1, 2022
139.34 SEK
Jan 1, 2023
-16.57 SEK
Jan 1, 2024
158.87 SEK
Jan 1, 2025
-9.18 SEK
The Vitrolife FCF Conversion history
YEARFCF ConversionYoY
-9.18 %-105.78%
158.87 %-1,058.94%
-16.57 %-111.89%
139.34 %+47.63%
94.39 %-19.51%
117.26 %+37.59%
85.23 %+55.88%
54.68 %-52.22%
114.44 %+30.06%
87.99 %-5.86%
93.47 %-25.42%
125.33 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vitrolife Stock analysis

What does Vitrolife do? Vitrolife AB is a Swedish biotech company specializing in the development and marketing of products for in vitro fertilization (IVF) and regenerative medicine. It was founded in 1994 and has over 390 employees worldwide. The company's main business is IVF, offering a wide range of essential products for IVF treatment such as culture media, devices for semen analysis and preparation, embryo transfer techniques, and products for biopsy examinations and cryopreservation. Vitrolife has a presence in 110 countries and has expanded its market to China where there is a high demand for fertility treatments. The company also offers medical equipment for regenerative treatments. Vitrolife is a leading player in the IVF industry known for its high product quality and innovation. It collaborates with universities and research institutions globally to improve IVF technology and success rates. The company places importance on sustainability and environmental protection, using 100% animal-free ingredients in their culture media and practicing recycling and waste reduction in their production facilities. In summary, Vitrolife offers a wide range of products for IVF and regenerative medicine, with a focus on supporting IVF treatments. The company is a leader in its industry and actively participates in research. It is committed to sustainability and environmental responsibility. Vitrolife is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vitrolife stock

FCF Conversion Rate (FCF/EBITDA) of Vitrolife is -9.18 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Vitrolife changed from 158.87 % to -9.18 %, representing a -105.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vitrolife since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vitrolife with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Vitrolife

All Key Metrics — Vitrolife